Testing treatment guided by tumor DNA for hormone positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have breast cancer that is stage II or III (not spread to distant organs)
- Your cancer is hormone receptor positive (especially estrogen receptor positive, with >20% cells staining) and HER2 negative
- Your doctor recommends chemotherapy as part of your treatment plan
- You have not had any treatment yet for this breast cancer
- You are willing and able to take pills by mouth and follow study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test (Signatera) to guide treatment can safely reduce the amount of chemotherapy after surgery for stomach or esophagus cancer. The goal is to see if less treatment is just as effective, based on whether cancer DNA is still detectable in your blood.
This study looks at whether a blood test called Signatera can help find small amounts of cancer DNA after surgery for early-stage endometrial cancer. The goal is to see if this test can help guide treatment decisions and improve outcomes.
This trial tests whether measuring tiny amounts of cancer DNA in the blood before standard treatment can help decide who might safely skip chemotherapy before surgery. It aims to see if a less intensive approach works as well for patients with early rectal cancer.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Hear when a new Early and Locally Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.